Last reviewed · How we verify
CTA101
At a glance
| Generic name | CTA101 |
|---|---|
| Also known as | CTA101 UCAR-T cell injection |
| Sponsor | Kai Lin Xu; Jun Nian Zheng |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy (EARLY_PHASE1)
- CTA101 UCAR-T Cell Injection for Treatment of Relapsed or Refractory CD19+ B-cell Acute Lymphoblastic Leukemia (PHASE1)
- CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |